Compugen | CGEN - Selling And Administration Expenses


Compugen reported $2.33M in Selling and Administration Expenses for its fiscal quarter ending in September of 2025.





Selling And Administration Expenses Change Date
Arca Biopharma USD 5.16M 346K Mar/2025
aTyr Pharma USD 4.8M 130K Sep/2025
Bio Path USD 1.26M 456K Mar/2025
Brainstorm Cell Therapeutics USD 1.78M 319K Mar/2025
Cara Therapeutics USD 4.64M 2.19M Mar/2025
Clal Biotechnology ILS 3.31M 513K Dec/2022
Compugen USD 2.33M 50K Sep/2025
Immunic USD -0.24 0.03 Sep/2024
Infinity Pharmaceuticals USD 3.75M 2.19M Jun/2023
Minerva Neurosciences USD 2.48M 58.79K Sep/2024
RedHill Biopharma USD 4.48M 1.52M Mar/2024
TherapeuticsMD USD 1.23M 90K Jun/2024